Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor

growth factor
carcinoma
vinflunine
transitional cell carcinoma
renal function
  • 271 views
  • 22 Sep, 2021
  • 595 locations
Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor. Its primary targets are Hepatocyte growth factor receptor protein (MET), vascular endothelial growth factor receptor 1-3 (VEGFR1-3), RET, AXL, FLT3 and KIT. Cabozantinib has been approved by the FDA for clinical treatment of progressive, metastatic medullary thyroid cancer. Recently published trials have …

neutrophil count
growth factor
carcinoma
transitional cell carcinoma
platinum-based chemotherapy
  • 46 views
  • 22 Sep, 2021
  • 12 locations
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

with cetrelimab in cisplatin-ineligible participants with metastatic or locally advanced urothelial cancer (UC) with select fibroblast growth factor receptor (FGFR) gene alterations and no prior

measurable disease
growth factor
cancer
systemic therapy
metastatic urothelial carcinoma
  • 95 views
  • 15 Sep, 2021
  • 207 locations
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer

The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or locally advanced urothelial cancer. This trial provides the first evaluation of bintrafusp alfa in

measurable disease
neutrophil count
carcinoma
pd-l1
liver metastasis
  • 0 views
  • 26 Jul, 2021
  • 15 locations
Study of Durvalumab Given With Chemotherapy Durvalumab in Combination With Tremelimumab Given With Chemotherapy or Chemotherapy in Patients With Unresectable Urothelial Cancer

This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or …

  • 202 views
  • 12 Sep, 2021
  • 287 locations
Derazantinib and Atezolizumab in Patients With Urothelial Cancer

The purpose of this study is to evaluate efficacy of derazantinib monotherapy or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth

measurable disease
growth factor
cancer
FGFR3
renal function
  • 9 views
  • 30 Jul, 2021
  • 113 locations
Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer

The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable urothelial cancer (UC).

neutrophil count
growth factor
vinflunine
systemic therapy
cancer
  • 0 views
  • 15 Sep, 2021
  • 28 locations
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer

This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma. Whenever possible, a new bone lesion or new/progressing soft tissue lesion will be chosen for biopsy as opposed to radiographically stable lesion. Patients will …

prostate specific antigen
carcinoma
antiandrogens
luteinizing hormone
serum testosterone
  • 7 views
  • 04 Jun, 2021
  • 1 location
Improve Checkpoint-blockade Response in Advanced Urothelial Cancer

This trial will include metastatic urothelial carcinoma patients who progressed during or after treatment with anti-PD(L)1 therapy and have been treated by a platinum-containing regimen, or are cisplatin-ineligible. Patients will receive either paclitaxel in combination with durvalumab (anti-PDL-1) and a single dose (300 mg) of tremelimumab (anti-CTLA4), or paclitaxel with …

neutrophil count
hormone therapy
metastatic urothelial carcinoma
immunosuppression
platinum-based chemotherapy
  • 0 views
  • 22 Mar, 2021
  • 1 location
Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer

This is a phase 2, single arm, two-stage study of abraxane with an anti-PD1/PDL1 (pembrolizumab) in cisplatin-ineligible patients with advanced urothelial cancer. Each cycle last 21-days

measurable disease
cancer
metastatic urothelial carcinoma
systemic therapy
vasectomy
  • 6 views
  • 24 Jan, 2021
  • 1 location